Jason Kingdon has been commercializing AI for over 25 years. He has a PhD from UCL Computer Science, he co-founded UCLs Intelligent Systems Lab in 1992 and pioneered one of the worlds first neural nets for live financial forecasting.
Jason is the Chairman and CEO of Blue Prism, a company that is unleashing the collaborative potential of humans and digital workers to transform the future of work, so every enterprise can exceed their business goals and drive growth with unmatched agility and speed.
Youve been involved in some form of AI for over 25 years now. What was it that attracted you to the space initially?
I became attracted to the artificial intelligence space because around the time I was in school earning my Ph.D. in intelligent systems and starting my career in research, there was a big boom in technology surrounding software with companies like Microsoft and Apple and Oracle. These organizations were using machines to solve problems people were facing on a daily basis and it was really enticing to become a part of this movement.
In 1992 you co-founded UCLs Intelligent Systems Lab. What were some of the projects that you worked on?
After co-founding UCLs Intelligent System Lab, I became founder/CEO of Searchspace, a successful UCL spinout project. We created Intelligent Transaction Monitoring Systems, which to this day are the global standard for money laundering and terrorist finance detection within the top-tier banks.
You were also responsible for introducing intelligent transaction monitoring on various exchanges such as the London Stock Exchange, and the New York Stock Exchange. Could you discuss the type of data that was being monitored and the type of AI implementation this was?
While we started Searchspace with broad ambitions for transaction monitoring, the project came to focus primarily on anti-money-laundering (AML) technology for banks and the middleware to link it to other systems. We produced an intelligent system that worked for the London Stock Exchange, the New York Stock Exchange, and others.
You also formed a private AI research lab called glass.ai. What was the mission of glass.ai?
The mission of glass.ai was and is to read and interpret vast quantities of textual data whether from websites, news, proprietary databases or other sources at scale, using AI to combine semantic analysis and resource crawling.
You then joinedBlue Prism as Executive Chairman, could you discuss what attracted you to this company?
I was drawn to Blue Prism in 2007 because of the ingenious way that theyd solved the operational inefficiencies within the banking sector where human workers perform repetitive tasks by interoperating between enterprise-wide IT systems. Traditional IT methods couldnt easily address this, as they were focusing on big ticket items, so a more agile automation solution was created by Blue Prism that could be run by non-technical business people but in a highly secure and regulated way.
What really impressed me was how theyd advanced business automation in such an elegant, light way taking the user interface seriously and repurposing it as a machine interface. Focusing on the interface meant that you can theoretically connect it to any past present or future system. The significance of this breakthrough was very clear to me especially when at Searchspace, clients always wanted extra things that involved integration with other systems.
Blue Prism solved these system interoperability challenges by pioneering robotic process automation (RPA) software that runs a pre-built, Digital Worker a software robot that automates tasks over any third-party system independently of machine APIs. Another breakthrough was that the Digital Worker uniquely used AI techniques to carry out tasks in the same way humans do but much faster and more accurately. I also saw RPA as a potential route for organizations being able to more easily test and then deploy any new transformative tech innovation.
The real light bulb moment came when I was introduced to a major UK online retailer who was an early Blue Prism RPA adopter. I was introduced to Kate an employee who ran the robots, and shed recently used them to reverse overpayments on 2,000 accounts. What amazed me was this complex activity was performed in less than 1 day, but without that robotic capability, the same activity would have taken a number of staff over three weeks to complete.
I believed that commercializing AI-powered automation in this way would have a profound effect on business and society. Blue Prism really understood and embraced this from the beginning and thats been reflected in the companys efforts every step of the way.
What has your journey with Blue Prism been like so far?
So far, it has been very exciting, fast-paced, challenging, all-encompassing and rewarding. Since investing in the business in 2007, Ive spent my time as Chairman driving our growth and vision strategy, and helping take the company public in 2016. This IPO provided the engine for growth and product development while providing the means for us to make critical investments, such as the acquisition of Thoughtonomy in 2019.
Im proud to say that over the last four years, weve gone from 60 to over 1,000 people, were selling in 170 countries to 70 commercial sectors and are approaching 1700 customers including many of the worlds biggest brands.
In fact, we recently reported achievingthe fastest revenue growthof all large UK public software companies for the fourth consecutive year in 2019.
As Chairman and CEO, Im now shaping and evolving our product roadmap that takes RPAinto the AI era while working tirelessly to promote the vision of a Digital Workforce for every enterprise. In my vision for the future, businesses will have a new organizational structure one-third human employees, one-third Digital Workers, and one-third core IT. Human workers will continue to provide strategy and creative thinking, Digital Workers will execute on business processes, and core IT will provide the underlying technology infrastructure and data storage.
With Thoughtonomy, in addition to its cloud capabilities, the acquisition is providing access to analytics that enable better ways of looking at the Digital Workers, seeing how they are deployed, seeing all the activities taking place. We are also working on ways to enhance the way Digital Workers and humans interact. The interplay between humans and Digital Workers is absolutely part and parcel of the enterprise vision and a Digital Workforce in every organization.
In the new operating environment recently created by COVID-19, our Digital Workers are arguably more important than ever in driving organizational adaptation and resilience. We are working to meet this demand by helping organizations to maintain business continuity and resilience to alleviate operational challenges through intelligent automation.
Blue Prism helps companies deliver robotic process automation (RPA) with a step-by-step methodology for a smooth implementation. For people not familiar with RPA, could you discuss what it is and how it can benefit different enterprises?
Our RPA technology runs an AI-powered, Digital Workforce; a self-organizing, multi-tasking, intelligent, processing resource thats trained and run by business to safely automate evermore complex, end-to-end, business activities faster and more accurately than humans. This enables our customers to exceed their business goals and drive meaningful growth, resilience and continuity with unmatched speed and agility.
To deliver results fast, Digital Workers arrive already pre-built and can simply be trained by business people without coding skills and put to work using a centralized operating system to draw, create and publish process automations. Digital Workers amplify gains by compounding how work is carried out as published automations and all related innovations are centralized to be shared, reused and improved by the whole business.
Digital Workers are managed by humans with our industry-leading, Robotic Operating Model delivery methodology that provides the most effective, proven way to; business-align, organize, identify, design, test, deploy and sustain process automations at scale so business-led, IT approved, enterprise-wide transformation is achieved. All Digital Workers are easy to deploy, manage, upgrade, scale and can be used by remote-working employees due to an availability on-premises, in the cloud, hybrid, or as an integrated SaaS solution.
We are helping organizations operating in all sectors achieve 6 areas of proven value delivery:
Could you discuss why you believe the Blue Prism solution is superior to competing RPA product offerings?
Our Digital Workers achieve greater transformational potential across the enterprise than other competitor robots as they possess business-led, no-code, centralized, design principles.
Our Digital Workers are also equipped with what we believe are the following totally unique attributes:
Competitive RPA offerings favor a form of digital assistant for a single person to perform all kinds of time-saving activity. And thats great, but its not taking full advantage of RPA in an enterprise environment. This is because robots that are distributed across individuals desktops and used in individual, soiled, contexts may help the individual but wont enable any benefits to be scaled and experienced by the whole enterprise.
Another major consideration is that due to a growing scarcity of software development skills, those robots that require any coding will ultimately suffer the same high costs and deployment delays as traditional IT projects.
What is the Blue Prism Digital Exchange (DX)?
The Blue Prism Digital Exchange (DX) is a ground-breaking intelligent automation app store and online community that offers an open ecosystem for intelligent automation capabilities. The Blue Prism DX offers connections to all transformative technologies which are simply dragged and dropped into process flows to be used for the continual testing, advancing, sharing and deployment of new automated innovations. This could be new AI, machine learning, chatbot and other cognitive capabilities. Blue Prisms DX is significant as its now driving those AI capabilities into the wider enterprise which is something that organizations would previously never have been able to experience.
Thank you for the interview. Anyone who wishes to learn more should visit Blue Prism.
Original post:
Robert Youngjohns, Chairman of the Board, ABBYY - Interview Series - Unite.AI
- The Ethical, Legal, and Social Issues Impacted by Modern ... - Hindawi - November 25th, 2022
- BSGM - The British Society for Genetic Medicine - November 25th, 2022
- Feasibility and ethics of using data from the Scottish newborn blood spot archive for research | Communications Medicine - Nature.com - October 7th, 2022
- Closing your health care practice: What you need to know - Medical Economics - October 7th, 2022
- Is the doctor's office heading for extinction? - Medical Economics - October 7th, 2022
- Abortion Access in the U.S.: What to Know on a State-By-State Level - Healthline - October 7th, 2022
- Students can create their own path with new ASU Online biology degree - ASU News Now - October 7th, 2022
- U.S. Releases an AI Bill Of Rights That Though Encouraging Won't Yet Move the Needle - JURIST - October 7th, 2022
- California Funds Research On Blocking Marijuana Monopolies And Protecting 'Legacy' Cannabis Strains - Marijuana Moment - October 7th, 2022
- Tips For Your Virtual Meetings With The FDA - Med Device Online - October 7th, 2022
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... - The Bakersfield Californian - October 7th, 2022
- MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress -... - October 7th, 2022
- Neighborhood deprivation and coronary heart disease in patients with bipolar disorder | Scientific Reports - Nature.com - October 7th, 2022
- Have Insurers Paid Too Much for Asbestos and Other Toxic Torts? - Claims Journal - August 19th, 2022
- Restrictive abortion laws are limiting the options parents have after receiving genetic test results, experts say - Yahoo Singapore News - August 19th, 2022
- Neurologists Discuss the Impact of Roe v. Wade Reversal on... : Neurology Today - LWW Journals - August 19th, 2022
- Abortion ruling prompts variety of reactions from states - ABC News - August 19th, 2022
- Is pregnancy possible after multiple failed IVF attempts? Can your frozen eggs and sperm be as healthy later? - The Indian Express - August 19th, 2022
- Meet the Expert: Focus on orthopaedics and VTE - Hospital Healthcare Europe - August 19th, 2022
- Egg Donation Process: From Application to Recovery - Healthline - July 6th, 2021
- Patent protection of mRNA vaccines and regulatory authorization - Lexology - July 6th, 2021
- EAPM: Presidency bridging conference a great success, HTA compromise agreed and data on the agenda - EU Reporter - July 6th, 2021
- Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies - PRNewswire - April 4th, 2021
- Legally blind Great Falls filmmakers share their vision in national challenge - Yahoo News - April 4th, 2021
- Pfizer Announces Vaccine Is 100% Protective Against Coronavirus In Kids As Young As 12 - Yahoo News - April 4th, 2021
- How the law will change in 2021 - Lexology - February 11th, 2021
- Writing is the best medicine - The London Economic - February 11th, 2021
- Misleading glyphosate-cancer study Part 2: 'Symptom of a widespread problem'Concerns about ideological activism in science research and communications... - February 11th, 2021
- The Error of Fighting a Public Health War With Medical Weapons - WIRED - January 2nd, 2021
- Moderna, Pfizer vaccine trials were the highest of quality: vaccine expert - Yahoo Money - January 2nd, 2021
- Celebrate the new year with this New Year's Eve fireworks show in SF - Yahoo News - January 2nd, 2021
- The movie industry will strengthen again around April or May: Screenvision CEO - Yahoo Money - January 2nd, 2021
- Congress overrides Donald Trump's veto of a defense policy bill in the first such rebuke of his presidency - Yahoo News - January 2nd, 2021
- How the pandemic enabled a robot revolution - Politico - December 4th, 2020
- The mink link: How COVID-19 mutations in animals affect human health and vaccine effectiveness - The Conversation CA - November 24th, 2020
- How vaccines get made and approved in the US - The Albany Herald - November 24th, 2020
- Legalization votes bring worries of increased youth marijuana use, but evidence remains murky - AberdeenNews.com - November 24th, 2020
- Your daily 6: Third vaccine looks effective, no single 'word of the year' and Trump team called 'a national embarrassment' - Ravalli Republic - November 24th, 2020
- Cybersecurity depends on the user - Modern Diplomacy - November 20th, 2020
- It's Been Exactly One Year Since the First Case of COVID Was Found in China - Newsweek - November 20th, 2020
- Risks and benefits of an AI revolution in medicine - Harvard Gazette - November 12th, 2020
- HHS eased oversight of Covid-19 tests though it knew of problems - STAT - November 3rd, 2020
- Who won this years Nobel science prizes? - The Economist - October 8th, 2020
- Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question? - The Leaflet - October 8th, 2020
- FDA Oversight of Laboratory-Developed Tests Continues To Evolve - JD Supra - October 8th, 2020
- One Sperm Donor. 36 Children. A Mess of Lawsuits. - The Atlantic - September 15th, 2020
- Nebraska Medical Bill initiative blocked from entering the November ballots - Cannabis Health Insider - September 15th, 2020
- Poaching pressure mounts on jaguars, the Americas' iconic big cat - Mongabay.com - September 15th, 2020
- 'There is a sense of being robbed': Olympian Caster Semenya loses appeal on testosterone rule - The World - September 15th, 2020
- Global Microbiome Sequencing Market Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026|Clinical-Microbiomics A/S; Diversigen;... - September 5th, 2020
- Legal and Regulatory Issues in Genetic Information ... - August 31st, 2020
- The legal aspects of genetic testing - Medical Defence Union - August 31st, 2020
- Their view: Now is not the time to legalize marijuana - Wilkes Barre Times-Leader - August 31st, 2020
- Weighing up the potential benefits and harms of comprehensive full body health checks - Croakey - August 24th, 2020
- Soon, India will have its dedicated vaccine portal: ICMR - ETHealthworld.com - August 24th, 2020
- Two Families, Two Fates: When the Misdiagnosis is Child Abuse - The Marshall Project - August 22nd, 2020
- Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy - Endpoints News - August 22nd, 2020
- Contact tracing apps may be ineffective for reducing Covid-19 spread: Study - ETHealthworld.com - August 22nd, 2020
- Global Microbiome Sequencing Market Size 2020 Review, Growth Strategy, Developing Technologies And Forecast By 2026|Charles River; CoreBiome, Inc.;... - August 19th, 2020
- Bill Jones: Working to create a culture of education - Wilkes Barre Times-Leader - August 19th, 2020
- Whats next for abortion legislation in the U.S.? - PBS NewsHour - July 10th, 2020
- No ethics when it comes to US enemies, even in the middle of a deadly pandemic - IOL - July 10th, 2020
- IML conducts the 5th National Convention on Medicine and Law - ETHealthworld.com - July 10th, 2020
- Wayne Medicine and Wayne Law professors team up to explore legal and ethical issues of wastewater monitoring for COVID-19 - The South End - June 28th, 2020
- Challenge trials aren't the answer to a speedy Covid-19 vaccine - STAT - June 28th, 2020
- Trump Suspends H-1B and Other Visas That Allow Foreigners to Work in the U.S. - The New York Times - June 24th, 2020
- Could the Montreal Neuro herald a paradigm shift in scientific research? - University Affairs - June 24th, 2020
- Next-Generation Sequencing Market: Understanding The Key Product Segments And Their Future During 2020 -2025 - 3rd Watch News - June 24th, 2020
- Meet 'Gastruloid': The First Human Embryo-like Model From Stem Cells That Could Soon Save Many Babie - Science Times - June 12th, 2020
- Could these senolytic drugs halt the spread of COVID-19? - Health Europa - June 12th, 2020
- The coronavirus vaccine frontrunners have emerged. Here's where they stand - BioPharma Dive - June 12th, 2020
- Regulating marine genetic resources in areas beyond national jurisdiction - The Daily Star - June 12th, 2020
- Vaccines have saved millions of lives, but history shows missteps can prove deadly - The Boston Globe - June 12th, 2020
- Quitting smoking might reduce severe coronavirus infection risk: Study - ETHealthworld.com - May 23rd, 2020
- Where Taiwan Can Make the Most of AI - Taiwan - Taiwan Business TOPICS - May 23rd, 2020
- WHO and IOC team up to improve health through sport - ETHealthworld.com - May 18th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 15th, 2020
- Medical School: Who gets in and why - Stuff.co.nz - May 15th, 2020
- Wilson Ighodalo: Addressing Substance Abuse as a Public Health Problem - THISDAY Newspapers - May 15th, 2020
- The Falsehoods of the 'Plandemic' Video - FactCheck.org - May 14th, 2020